Login to Your Account



MyVax Misses Statistical Hurdle, Genitope Plunges

By Aaron Lorenzo


Monday, July 31, 2006
In a disappointing case of déj vu, investors drove down shares in Genitope Corp. by 48.6 percent after learning that a Phase III study of its lead cancer treatment would last longer than expected. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription